Weekly Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Ratings as of May 17, 2018

May 17, 2018 - By Vernon Prom

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Corporate Logo
Big Money Sentiment increased to 3 in 2017 Q4. It has change of 2.21, from 2017Q3’s 0.79. The ratio increased due to Dicerna Pharmaceuticals, Inc. positioning: 6 sold and 5 reduced. 18 funds amassed stakes and 15 increased stakes. Investors holded 10.37 million in 2017Q3 but now own 29.10 million shares or 180.62% more.
Bnp Paribas Arbitrage Sa reported 32 shs stake. Bridger Management Limited Liability Company stated it has 905,998 shs. Vanguard Group holds 589,573 shs. Fmr Ltd Liability reported 0% of its capital in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Ra Cap Mngmt Limited Liability Corp owns 3.75% invested in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) for 4.97 million shs. Morgan Stanley reported 1,874 shs. Dimensional Fund Advisors Limited Partnership reported 18,244 shs stake. Ecor1 Ltd Co owns 4.84M shs for 4.92% of their capital. Birchview Capital Limited Partnership, a Vermont-based fund reported 45,000 shs. 1,016 were reported by Royal Bancorp Of Canada. Moreover, Jpmorgan Chase & Co has 0% invested in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) for 35,423 shs. Panagora Asset holds 7,533 shs. Northern reported 36,282 shs. 168,400 are owned by Deutsche Savings Bank Ag. 550,000 were accumulated by 683 Cap Mngmt Ltd.

Dicerna Pharmaceuticals, Inc. registered $1.57 million net activity with 1 insider buy and 4 selling transactions since December 18, 2017. Brown Bob D also sold $145,035 worth of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) on Wednesday, May 9. Weissman James B sold $116,545 worth of stock or 8,965 shs.

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Ratings Coverage

Total analysts of 8 have positions in Dicerna Pharmaceuticals (NASDAQ:DRNA) as follows: 4 rated it a “Buy”, 0 with “Sell” and 4 with “Hold”. The positive are 50%. Since January 16, 2018 according to StockzIntelligence Inc Dicerna Pharmaceuticals has 8 analyst reports. On Tuesday, March 27 the stock of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) has “Hold” rating given by FBR Capital. On Wednesday, April 11 the stock of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) earned “Buy” rating by Cowen & Co. On Monday, February 5 the stock has “Buy” rating by SunTrust. On Friday, March 9 the stock has “Buy” rating by Stifel Nicolaus. On Friday, March 9 the firm has “Hold” rating by Chardan Capital Markets given. The company rating was downgraded by H.C. Wainwright on Friday, March 23. Listed here are Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) PTs and latest ratings.

11/04/2018 Broker: Cowen & Co Rating: Buy Initiate
28/03/2018 Broker: B. Riley & Co Rating: Neutral New Target: $10 Initiates Coverage On
27/03/2018 Broker: FBR Capital Rating: Hold New Target: $10.0000 Initiate
23/03/2018 Broker: H.C. Wainwright Old Rating: Buy New Rating: Neutral Old Target: $7 Downgrade
09/03/2018 Broker: Chardan Capital Markets Rating: Hold Initiate
09/03/2018 Broker: Stifel Nicolaus Old Rating: Buy New Rating: Buy Old Target: $10 New Target: $17 Maintain
05/02/2018 Broker: SunTrust Rating: Buy New Target: $13.0 Initiate
16/01/2018 Broker: Evercore Rating: Outperform New Target: $14 Initiates Coverage On

DRNA is reaching $13.76 during the last trading session, after decreased 0.04%.Currently Dicerna Pharmaceuticals, Inc. is uptrending after 274.53% change in last May 17, 2017. DRNA has also 29,107 shares volume. DRNA outperformed by 262.98% the S&P500.

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for rare, chronic liver, cardiovascular, and viral infectious diseases in the United States and internationally.The firm is worth $712.73 million. The companyÂ’s preclinical stage development programs include DCR-PHXC for the treatment of primary hyperoxaluria type 1; DCR-PCSK9, which targets the PCSK9 gene in the treatment of statin-refractory patients with hypercholesterolemia; and DCR-HBV for the treatment of chronic hepatitis B virus infection, as well as other product candidates for use in the treatment of cardiovascular and chronic liver diseases.Last it reported negative earnings. It has a research collaboration and license agreements with Kyowa Hakko Kirin Co., Ltd.; City of Hope, an academic research and medical center; and Plant Bioscience Limited.

More recent Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) news were released by Businesswire.com, Benzinga.com and Streetinsider.com. The first one has “Dicerna Reports First Quarter 2018 Financial and Operating Results and Provides Corporate Update” as a title and was released on May 14, 2018. The next is “Earnings Scheduled For May 14, 2018” on May 14, 2018. And last was released on May 15, 2018, called “Dicerna Pharmaceuticals (DRNA) PT Raised to $18 at Stifel”.

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.